Viking Therapeutics (VKTX) Stock Still Looks Stretched After A 382% Run

Viking Therapeutics stock has delivered a very large 5 year gain, yet on broad valuation checks it still screens as expensive rather than a clear bargain. For investors trying to weigh the recent share price against fundamentals, the company now looks more like a growth story that the market already prices on the rich side.

• Over the past 5 years, Viking Therapeutics has returned about 382.1%, which points to very strong long term share price momentum that can leave less room for error if expectations change.
• The key potential catalyst is progress in clinical trials for lead obesity drug VK2735 and use of the company’s US$502 million cash balance to fund development, while the main risk is that trial outcomes or timelines fall short of expectations and undermine confidence in future cash generation.
• The stock scores 0 out of 6 on broad valuation checks, which points to Viking Therapeutics looking expensive on these measures rather than like an obvious value opportunity.

The issue now is whether Viking Therapeutics’ current price leaves enough potential reward to justify the risks that come with this valuation profile.

Broaden your watchlist beyond Viking Therapeutics by scanning 45 high quality undervalued stocks, which pairs stronger valuation checks with solid business quality.

Has Viking Therapeutics Run Too Far on Book Value?

P/B is often a useful way to think about Viking Therapeutics because the balance sheet and cash position matter a lot while the company is still loss making. On this metric, the stock trades on a P/B of about 9.4x, compared with an industry average around 2.5x and a peer group closer to 4.8x. That is a very big premium for a biotech that is still working through clinical trials rather than generating material free cash flow.

Despite Viking Therapeutics recently highlighting its US$502 million cash balance as it advances VK2735, the current P/B suggests the market is already assigning a high value to future success. The valuation model also heavily penalises the company for recent losses, which pushes this framework to flag the shares as screening very expensive rather than pointing to any precise “fair” multiple. For readers, the key takeaway is that most of the optimism around the pipeline now appears reflected in the book value multiple.

On the P/B yardstick, Viking Therapeutics stock currently looks expensive relative to typical biotech peers.

See what the numbers say about this price — find out in our valuation breakdown.

The Viking Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Viking Therapeutics valuation puzzle leaves off by spelling out what would need to happen to future growth, margins and earnings for the stock to be worth materially more or less than today's price, and they sit on the company’s Community page. Rather than relying on a single multiple or model, each narrative lays out the assumptions behind its fair value so you can later compare them with reported results.

One of the top community narratives on Viking Therapeutics: 74% undervalued

"The oral VK2735 program, supported by Phase II data with double digit weight loss percentages and plans to move into Phase III, gives Viking a second high value product path that may diversify future revenue sources and create operating leverage if both oral and injectable share the same active molecule…"

Read one of the top narratives on Viking Therapeutics

Do you think there's more to the story for Viking Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

Viking Therapeutics now screens as overvalued on broad market multiples, with a rich P/B and a wide gap to typical biotech peers. That does not rule out further upside, but it does mean the market already prices in a lot of success for VK2735 and the wider pipeline. The key question from here is whether future trial results and development progress are strong and timely enough to support that premium before sentiment or expectations shift.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com